Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

427
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

417
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
417
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
Imaging Studies for Cardiovascular System III: X-Ray01:20

Imaging Studies for Cardiovascular System III: X-Ray

447
The most common cardiovascular diagnostic test is an X-ray. It produces images of the heart, blood vessels, and adjacent structures.
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
447

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy.

Cardiovascular research·2026
Same author

Sex-Based Differences in Management and Outcomes of Patients Admitted or Transferred to Advanced Therapy Centers for Heart Failure.

Journal of clinical medicine·2026
Same author

Pregnancy-Associated Spontaneous Coronary Artery Dissection in a 32-Year-Old Woman With Postpartum Hemorrhage.

JACC. Case reports·2026
Same author

Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.

International journal of cardiology·2026
Same author

Protecting the Heart Against Anthracyclines: The Elusive Search for the Optimal Cardiomyocyte Model.

JACC. Basic to translational science·2026
Same author

Functional Genomics Illuminates Mechanisms of Anthracycline Cardiotoxicity.

JACC. CardioOncology·2026

Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K

Fluoropyrimidine-Associated Cardiotoxicity.

Jaya Kanduri1, Luis Alberto More2, Anuradha Godishala3

  • 1Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

Cardiology Clinics
|October 8, 2019
PubMed
Summary

Fluoropyrimidine chemotherapy can cause heart damage, including chest pain and heart attacks. More research is needed to understand these cardiac risks and develop effective cardioprotection strategies.

Keywords:
5-FUCapecitabineCardiotoxicityChemotherapyCoronary vasospasmFluoropyrimidines

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Fluoropyrimidines are vital chemotherapy drugs for solid tumors.
  • Cardiotoxicity is a significant limitation to fluoropyrimidine use.
  • The exact incidence and mechanisms of fluoropyrimidine-induced cardiotoxicity are not fully understood.

Purpose of the Study:

  • To review the clinical presentations of fluoropyrimidine cardiotoxicity.
  • To explore proposed mechanisms of cardiotoxicity.
  • To discuss current therapeutic strategies and the need for evidence-based cardioprotection.

Main Methods:

  • Literature review of clinical presentations and proposed mechanisms.
  • Analysis of existing therapeutic and prophylactic interventions.
  • Identification of research gaps and future directions.

Main Results:

  • Fluoropyrimidine cardiotoxicity presents diversely, including chest pain, myocardial infarction, cardiomyopathy, arrhythmia, and sudden death.
  • Potential mechanisms involve coronary vasospasm, endothelial dysfunction, direct myocardial toxicity, myocarditis, and Takotsubo cardiomyopathy.
  • Current interventions mainly focus on coronary vasospasm.

Conclusions:

  • Fluoropyrimidine cardiotoxicity is a serious concern with varied clinical manifestations and proposed mechanisms.
  • Targeting coronary vasospasm is a primary therapeutic approach.
  • Prospective studies are essential to establish evidence-based cardioprotection protocols for patients receiving fluoropyrimidines.